m
mbiomics
Germany · Biotech
mbiomics develops live bacterial therapeutics using precisely designed microbial communities.
Product
mbiomics is a Munich biotechnology company developing oral treatments composed of live bacterial strains. Its platform combines precision microbiome analysis, computational design, screening and manufacturing to build defined microbial communities for pharmaceutical use.
The company is advancing MBX-116 as a potential companion treatment to immune checkpoint inhibitors in melanoma. It also develops a broader pipeline for diseases influenced by the gut microbiome, including autoimmune and neurological conditions.
Funding history
2 rounds · 2 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series A third close | €12M | Bayern Kapital — ParticipantMIG Fonds — Participant | |
| Series A first close | €13M | MIG Capital AG — LeadBayern Kapital — ParticipantHigh-Tech Gründerfonds — Participant |
Investors
Bayern KapitalJoined Series A third close · Joined Series A first closeMIG FondsJoined Series A third closeMIG Capital AGLed Series A first closeHigh-Tech GründerfondsJoined Series A first closeCoverage
weeklyWeekly funding picks, April 27–May 3: battery swapping, microbiome drugs and engineering dataApr 28, 2026mbiomics · Series A third closeMar 23, 2023mbiomics · Series A first closeSimilar companies
SSSunlit SeedlingsSunlit Seedlings measures biodiversity and microbial activity to help organisations assess and redesign ecosystems.Undisclosed · Corporate investment
BiomatterBiomatter designs custom enzymes for pharmaceutical, diagnostic, agricultural and industrial applications.$18M · Series A
OOOrakl OncologyCombines patient-derived tumour organoids, clinical data and AI to help pharmaceutical companies develop cancer treatments.$34M · Series A